Opioid-sparing effect, but limited analgesic efficacy, with preop gabapentinoids in THA .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(10):9 BMC Musculoskelet Disord. 2016 Aug 30;17(1):373Seven randomized controlled trials were included in this meta-analysis evaluating the efficacy and safety of preoperative gabapentin and pregabalin for postoperative analgesia following total hip arthroplasty. In all studies, gabapentin and/or pregabalin were compared to either placebo or no intervention. Pooled results demonstrated significantly lower cumulative morphine consumption with gabapentin compared to control up to 24 hours after surgery, and with pregabalin compared to control up to 48 hours after surgery. In contrast, pooled pain scores at rest or on mobilization did not demonstrate significantly lower scores with either gabapentin or pregabalin compared to control. In fact, pain scores during mobilization after 48 hours were significantly higher among gabapentin groups compared to control groups.
Were the search methods used to find evidence (original research) on the primary question or questions stated?
Was the search for evidence reasonably comprehensive?
Were the criteria used for deciding which studies to include in the overview reported?
Was the bias in the selection of studies avoided?
Were the criteria used for assessing the validity of the included studies reported?
Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?
Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?
Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?
Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?
How would you rate the scientific quality of this evidence?
Ja = 1
Ungewiss = 0.5
Nicht relevant = 0
Nein = 0
Die Bewertung der Berichtskriterien bewertet die Transparenz, mit der die Autoren die methodischen und studienspezifischen Merkmale der Studie in der Veröffentlichung angeben. Die Bewertung ist in fünf Kategorien unterteilt, die im Folgenden vorgestellt werden.
4/4
Introduction
4/4
Accessing Data
3/4
Analysing Data
4/4
Results
1/4
Discussion
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
Der Fragilitätsindex ist ein Instrument, das bei der Interpretation signifikanter Ergebnisse hilft und ein Maß für die Stärke eines Ergebnisses liefert. Der Fragilitätsindex gibt die Anzahl der aufeinanderfolgenden Ereignisse an, die zu einem dichotomen Ergebnis hinzugefügt werden müssen, damit das Ergebnis nicht mehr signifikant ist. Eine kleine Zahl steht für ein schwächeres Ergebnis und eine große Zahl für ein stärkeres Ergebnis.
Warum wurde diese Studie jetzt benötigt?
One of the most important areas of research regarding perioperative treatment of patients undergoing total hip arthroplasty is postoperative analgesia. Patient-controlled analgesia with opioids remains a standard method of analgesia, although the undesirable side-effects of opioids have led to an emphasis on trying to limit their administration to only rescue analgesia and improve primary treatment. Gabapentinoids, such as gabapentin and pregabalin, have been suggested as medications with possible analgesic efficacy in these patients.
Was war die wichtigste Forschungsfrage?
What are the efficacy and safety profiles of preoperative gabapentin and pregabalin, compared to control, for analgesia following total hip arthroplasty?
- Pooled cumulative morphine consumption was significantly lower among gabapentin groups compared to control after 24h (MD -2.65 [95%CI -3.67, -1.63]; p<0.001) but not 48h (MD 0.00 [95%CI -7.69, 7.69]; p=1.000), while it was significantly lower for pregabalin compared to control after both 24 (MD -19.42 [95%CI -11.72, -3.93]; p<0.001) and 48h (MD -33.02 [95%CI -45.86, -20.19]; p<0.001).
- VAS pain at rest and at 24h did not significantly differ between gabapentin and control (MD 0.32 [95%CI -0.03, 0.67]; p=0.076), and pregabalin and control (MD -3.05 [95%CI -11.63, 5.53]; p=0.486). VAS pain at rest was significantly higher with gabapentin compared to control after 48h (MD 0.41 [95%CI 0.00-0.81]; p=0.049).
- VAS pain with mobilization between gabapentin and control did not significantly differ after 24h (MD 0.72 [95%CI -0.23, 1.66]), and was significantly higher among gabapentin groups after 48h (MD 1.90 [95%CI 0.04-3.75]; p=0.045). No significant difference in VAS pain with mobilization between pregabalin and control was observed after 24h (MD -0.78 [95%CI -6.91, 5.35]; p=0.803).
- No significant difference between gabapentin/pregabalin groups overall and control groups was observed in the incidences of vomiting (RR 0.95 [95%CI 0.47-1.92]), dizziness (RR 0.82 [95%CI 0.51-1.33]), or pruritus (RR 0.89 [95%CI 0.57-1.39]). A significantly lower incidence of nausea was observed with gabapentin/pregabalin groups compared to control (RR 0.49 [95%CI 0.27-0.92]).
Was sollte ich mir besonders merken?
In total hip arthroplasty, an opioid-sparing effect was observed with preoperative gabapentin up to 24 hours after surgery, and with preoperative pregabalin up to 48 hours after surgery. However, neither treatment provided a significant benefit compared to the control group for pain at rest or on movement. In contrast, pooled pain scores during movement were actually higher in gabapentin groups compared to control groups after 48 hours.
Wie wird sich dies auf die Behandlung meiner Patienten auswirken?
While there may be a short-term reduction in opioid requirement with the use of either gabapentin or pregabalin following total hip arthroplasty, these interventions do not appear to significantly reduce short-term pain scores in patients. Therefore, their role in postoperative analgesia following total hip arthroplasty should be scrutinized based on the currently available data. It is important to note limitations of the available body of evidence, as only 2-3 studies were available to separately assess the efficacy and safety of gabapentin and pregabalin each indicating the need to further large randomized controlled trials.
HAFTUNGSAUSSCHLUSS
Der Inhalt dieser Seite dient nur zu Informationszwecken und ist nicht als Ersatz für professionelle medizinische Beratung, Diagnose oder Behandlung gedacht. Wenn Sie eine medizinische Behandlung benötigen, wenden Sie sich immer an Ihren Arzt oder suchen Sie die nächstgelegene Notaufnahme auf. Die Meinungen, Überzeugungen und Standpunkte, die von den Personen auf dieser Seite geäußert werden, spiegeln nicht die Meinungen, Überzeugungen und Standpunkte von OrthoEvidence wider.
0 von 4 monatliche KOSTENLOSE Artikel freigeschaltet
